{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06312176\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["sacituzumab tirumotecan"],["sacituzumab tirumotecan","pembrolizumab"]],"indication":"HR+/HER2- unresectable locally advanced or metastatic breast cancer","name":"TroFuse-010","nct_id":"NCT06312176","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-010-nct06312176. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.","label":"Arm A: Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up to 18 administrations (up to \\~2 years).","label":"Arm B:Pembrolizumab + Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"At the physician's discretion, participants receive chemotherapy of 80 mg/m\\^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m\\^2 of paclitaxel once every 4 weeks (Q4W) via IV infusion OR 100 mg/m\\^2 of nab-paclitaxel Q4W via IV infusion OR 1000 mg/m\\^2 of capecitabine every 3 weeks (Q3W) orally OR 50 mg/m\\^2 of liposomal doxorubicin once every 4 weeks (Q4W) via IV infusion, until progressive disease or discontinuation.","label":"Arm C: Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-04-12","type":"ESTIMATED"},"conditions":["Breast Neoplasms"],"enrollment":{"count":1200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["MK-2870"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Paclitaxel","otherNames":["TAXOL®"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["ABRAXANE®"],"type":"DRUG"},{"name":"Capecitabine","otherNames":["XELODA®"],"type":"DRUG"},{"name":"Liposomal doxorubicin","otherNames":["DOXIL®"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-07-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)","timeFrame":"Up to ~40 months"},{"measure":"PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)","timeFrame":"Up to ~40 months"}],"references":[],"start_date":{"date":"2024-04-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","url":"https://clinicaltrials.gov/study/NCT06312176"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-010-nct06312176"}